Karyopharm shares rise 10.16% intraday after Cantor Fitzgerald initiates Overweight rating citing probability-weighted value.

Karyopharm Therapeutics surged 10.16% intraday after Cantor Fitzgerald initiated coverage with an Overweight rating, citing the biotech’s strong price momentum and probability-weighted analysis of its pipeline. The analyst’s bullish stance, combined with the stock trading below its fair value, likely spurred investor optimism. While the company’s Q4 and full-year 2025 earnings report is scheduled for February 12, 2026, the immediate intraday rally aligns more directly with the new analyst rating than the future earnings announcement.